Table 1.
Analysis of the patients who developed GBS after allogeneic BMT.
| Age/gender | Tumor | GVHD (at the time of GBS) | GBS on set after BMT | CMV antigenomia | Treatment | Outcome | Cause |
|---|---|---|---|---|---|---|---|
| 50/male | AML | Chronic GVHD | 114 days | (+) | IVIg | Recovery | GVHD > CMV |
| 64/male | WM | Unclear | (−) | IVIG | Alive | ||
| 59/male | AML | Unclear | (−) | IVIG, rituximab | Not known | ||
| 37/male | AML | Unclear | (−) | IVIG | Alive | ||
| 44/female | MDS | Unclear | (+) | IVIG, rituximab | Alive | ||
| 58/female | NHL | (−) | Steroids, IVIG, plasmapheresis, cyclosporin | Recovery following cyclosporin | Discontinuation of immunosuppressant, GVHD | ||
| 58/male | MDS | Possible chronic GVHD | 69 days | (−) | IVIG, rituximab, steroids | Alive | Possible GVHD |
| 34/female | ALL | Acute GVHD | 78 days | (+) | IVIG, cyclosporin | Recovery | Immune-mediated |
| 40/female | CML | Acute GVHD | Steroids, cyclosporin, IVIG, plasmapheresis | Partial initial improvement but ultimate death | GVHD | ||
| 18–60 | MDS | 142 days | (+) | IVIG | Death following respiratory failure | ||
| 18–60 | NHL | Chronic GVHD | 160 days | (+) | IVIG, rituximab, plasmapheresis | Death following respiratory infection | |
| 18–60 | AML | Possible chronic GVHD | 101 days | (+) | No specific treatment | Death following respiratory failure | |
| 16/male | T cell ALL | 6 days | (−) | IVIG | Death | Ara-C treatment prior to transplantation | |
| 17/male | T cell Lymphoma | 3 days | (−) | IVIG | Death | Ara-C treatment prior to transplantation | |
| 18/male | T cell ALL | 2 days | (−) | IVIG | Death | Ara-C treatment prior to transplantation | |
| 34/female | CML | No GVHD | 120 days | Plasmapheresis | Improvement | ||
| 27/male | HD | No GVHD | 450 days | Plasmapheresis | Recovery | ||
| 34/male | AML | Mild GVHD | 120 days | Plasmapheresis | Improvement | ||
| 59/female | CML | Mild GVHD | 330 days | (−) | IVIG, plasmapheresis | Death | |
| 43/male | CML | Acute GVHD | 163 days | (+) | IVIG, plasmapheresis | Very slight neurological deficiency | HHV-6 |
| 23/male | AML | No GVHD | 42 days | IVIG, plasmapheresis | Death | CMV |
GVHD—graft versus host disease; BMT—bone marrow transplant; CVM—cytomegalovirus; AML—acute myeloid leukemia; CML—chronic myeloid leukemia; MDS—myelodysplastic syndrome; NHL—Non-Hodgkin's Lymphoma; HD—Hodgkin's disease; WM—Waldenstrom macroglobulinemia; ALL—acute lymphoblastic leukemia; IVIG—intravenous immunoglobulin.